<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
The FDA has accepted for review Bristol Myers Squibb & Co’s (NYSE: BMY) deucravacitinib for the treatment of adults with moderate to severe plaque psoriasis. The European Medicines Agency has also validated the deucravacitinib marketing application for plaque psoriasis.
...read full article on Benzinga
